©2024 Stanford Medicine
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
Not Recruiting
Trial ID: NCT01927406
Purpose
The purpose of this study is to evaluate the potential secondary beneficial effect of
prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients. This study aims
to determine if PA would change the course of the orbitopathy in TED patients by altering the
progression of the common features of TED, including fatty hypertrophy, proptosis, eyelid
retraction and optic nerve compression. The eyes with thyroid eye disease and elevated
intraocular pressure will be randomised to the PA treatment and the other eye will serve as a
control eye and will be treated with Timolol.
Official Title
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
Stanford Investigator(s)
Andrea Lora Kossler, MD, FACS
Assoc Professor of Ophthalmology
Eligibility
Inclusion Criteria:
- mild or moderate to severe thyroid eye disease in one or both eyes
- age > 18 years
- informed consent
- intraocular pressure > 21 mmHg or glaucoma suspect or glaucoma diagnosed in one or
both eyes
- not on current prostaglandin analog intraocular pressure lowering therapy
Exclusion Criteria:
- sight threatening thyroid eye disease
- children < 18 years old
- patients that are not compliant with treatment or follow-up
- patients already on prostaglandin analog treatment
- patients that undergo cosmetic periocular procedures during the study will be excluded
from further follow up
- patients that cannot tolerate prostaglandin analog treatment.
- patients with bilateral thyroid eye disease and elevated intraocular pressures that
cannot tolerate treatment with timolol or an alternative intraocular pressure lowering
medication such as trusopt, combigan, cosopt.
Intervention(s):
drug: Prostaglandin Analog
drug: Timolol
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Barbara Bartlett
650-724-9259